FDA approves new treatment for sickle cell disease from LA BioMed company

We want to shout from the rooftops the outstanding news that Endari, an L-glutamine oral powder for patients with sickle cell disease provided by LA BioMed spinoff Emmaus Medical, has been approved by the FDA. It caps a remarkable 25-year journey by founder and CEO of Emmaus, Dr. Nihara, whose research into L-glutamine and his work with patients at Harbor-UCLA, along with LA BioMed’s unflinching support, has made this great milestone a reality. “To echo Supervisor Ridley-Thomas, this spells HOPE loud and clear for sufferers of this awful disease," says Rohit Shukla, CEO of Larta Institute.

As far back as 1999 Larta Institute believed in Emmaus Medical, providing the Company with a slot during our Venture Salon series of live presentation events in Los Angeles.  Emmaus has gone on to raise $100M.

LA BioMed is an LA County gem, headquartered on the Harbor-UCLA campus.  The non-profit institution has major plans to provide support to researchers, including new research facilities and a new incubator for promising spinoffs.  Larta Institute is proud to be closely affiliated with LA BioMed, including the launch of the LA BioMed CAP (Larta's commercialization accelerator program) this summer.

Congratulations to Emmaus Medical on this significant achievement!

Read about Endari here.